Intravenous thrombolysis in acute ischaemic stroke: Optimising its use in routine clinical practice

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Stroke is a common and important medical problem. Intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; rtPA) is the only available direct treatment that reduces neurological injury following ischaemic stroke. Strong efficacy data from randomised, controlled trials support the use of intravenous thrombolysis to improve outcomes for patients with acute ischaemic stroke. Numerous studies have provided effectiveness data that demonstrate that intravenous thrombolytic therapy can be given safely outside clinical trial settings. However, effectiveness studies have demonstrated that intravenous thrombolytic therapy is often given despite protocol violations when it is prescribed in routine clinical practice. Protocol violations must be avoided because they are associated with adverse events including higher mortality and increased haemorrhagic complications. Although thrombolytic therapy with alteplase is currently being used in only

Original languageEnglish (US)
Pages (from-to)295-302
Number of pages8
JournalCNS Drugs
Volume19
Issue number4
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Thrombolytic Therapy
Tissue Plasminogen Activator
Stroke
Randomized Controlled Trials
Clinical Trials
Mortality
Wounds and Injuries
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Pharmacology

Cite this

Intravenous thrombolysis in acute ischaemic stroke : Optimising its use in routine clinical practice. / Bravata, Dawn.

In: CNS Drugs, Vol. 19, No. 4, 2005, p. 295-302.

Research output: Contribution to journalArticle

@article{78d5b869025d4af88b88266e4e9f26bd,
title = "Intravenous thrombolysis in acute ischaemic stroke: Optimising its use in routine clinical practice",
abstract = "Stroke is a common and important medical problem. Intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; rtPA) is the only available direct treatment that reduces neurological injury following ischaemic stroke. Strong efficacy data from randomised, controlled trials support the use of intravenous thrombolysis to improve outcomes for patients with acute ischaemic stroke. Numerous studies have provided effectiveness data that demonstrate that intravenous thrombolytic therapy can be given safely outside clinical trial settings. However, effectiveness studies have demonstrated that intravenous thrombolytic therapy is often given despite protocol violations when it is prescribed in routine clinical practice. Protocol violations must be avoided because they are associated with adverse events including higher mortality and increased haemorrhagic complications. Although thrombolytic therapy with alteplase is currently being used in only",
author = "Dawn Bravata",
year = "2005",
doi = "10.2165/00023210-200519040-00002",
language = "English (US)",
volume = "19",
pages = "295--302",
journal = "CNS Drugs",
issn = "1172-7047",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Intravenous thrombolysis in acute ischaemic stroke

T2 - Optimising its use in routine clinical practice

AU - Bravata, Dawn

PY - 2005

Y1 - 2005

N2 - Stroke is a common and important medical problem. Intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; rtPA) is the only available direct treatment that reduces neurological injury following ischaemic stroke. Strong efficacy data from randomised, controlled trials support the use of intravenous thrombolysis to improve outcomes for patients with acute ischaemic stroke. Numerous studies have provided effectiveness data that demonstrate that intravenous thrombolytic therapy can be given safely outside clinical trial settings. However, effectiveness studies have demonstrated that intravenous thrombolytic therapy is often given despite protocol violations when it is prescribed in routine clinical practice. Protocol violations must be avoided because they are associated with adverse events including higher mortality and increased haemorrhagic complications. Although thrombolytic therapy with alteplase is currently being used in only

AB - Stroke is a common and important medical problem. Intravenous thrombolysis with alteplase (recombinant tissue plasminogen activator; rtPA) is the only available direct treatment that reduces neurological injury following ischaemic stroke. Strong efficacy data from randomised, controlled trials support the use of intravenous thrombolysis to improve outcomes for patients with acute ischaemic stroke. Numerous studies have provided effectiveness data that demonstrate that intravenous thrombolytic therapy can be given safely outside clinical trial settings. However, effectiveness studies have demonstrated that intravenous thrombolytic therapy is often given despite protocol violations when it is prescribed in routine clinical practice. Protocol violations must be avoided because they are associated with adverse events including higher mortality and increased haemorrhagic complications. Although thrombolytic therapy with alteplase is currently being used in only

UR - http://www.scopus.com/inward/record.url?scp=17844407412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17844407412&partnerID=8YFLogxK

U2 - 10.2165/00023210-200519040-00002

DO - 10.2165/00023210-200519040-00002

M3 - Article

C2 - 15813643

AN - SCOPUS:17844407412

VL - 19

SP - 295

EP - 302

JO - CNS Drugs

JF - CNS Drugs

SN - 1172-7047

IS - 4

ER -